Teacher Retirement System of Texas Sells 2,576 Shares of Progyny, Inc. $PGNY

Teacher Retirement System of Texas decreased its holdings in Progyny, Inc. (NASDAQ:PGNY) by 10.7% in the 2nd quarter, Holdings Channel.com reports. The firm owned 21,526 shares of the company’s stock after selling 2,576 shares during the period. Teacher Retirement System of Texas’ holdings in Progyny were worth $474,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of PGNY. Nordea Investment Management AB raised its holdings in Progyny by 0.6% in the 2nd quarter. Nordea Investment Management AB now owns 183,362 shares of the company’s stock valued at $4,052,000 after acquiring an additional 1,140 shares in the last quarter. Voya Investment Management LLC grew its holdings in shares of Progyny by 258.2% during the 1st quarter. Voya Investment Management LLC now owns 185,495 shares of the company’s stock worth $4,144,000 after purchasing an additional 133,703 shares in the last quarter. Millennium Management LLC increased its position in shares of Progyny by 7.5% in the first quarter. Millennium Management LLC now owns 1,302,890 shares of the company’s stock worth $29,107,000 after purchasing an additional 90,367 shares during the period. Acadian Asset Management LLC raised its stake in Progyny by 243.6% in the first quarter. Acadian Asset Management LLC now owns 205,650 shares of the company’s stock valued at $4,589,000 after purchasing an additional 145,802 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd raised its stake in Progyny by 88.0% in the second quarter. Y Intercept Hong Kong Ltd now owns 56,196 shares of the company’s stock valued at $1,236,000 after purchasing an additional 26,310 shares in the last quarter. Institutional investors own 94.93% of the company’s stock.

Insider Activity

In other news, EVP Allison Swartz sold 2,398 shares of the stock in a transaction on Thursday, August 28th. The stock was sold at an average price of $22.96, for a total value of $55,058.08. Following the completion of the transaction, the executive vice president directly owned 79,697 shares in the company, valued at approximately $1,829,843.12. This represents a 2.92% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold 5,395 shares of company stock worth $124,211 in the last three months. 9.40% of the stock is currently owned by corporate insiders.

Progyny Trading Up 24.2%

PGNY stock opened at $22.37 on Monday. The firm has a 50-day moving average price of $20.91 and a 200-day moving average price of $21.85. Progyny, Inc. has a 12 month low of $13.39 and a 12 month high of $26.76. The stock has a market capitalization of $1.92 billion, a P/E ratio of 35.51, a price-to-earnings-growth ratio of 1.90 and a beta of 1.29.

Progyny (NASDAQ:PGNY) last released its quarterly earnings data on Thursday, November 6th. The company reported $0.15 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.39 by ($0.24). The company had revenue of $313.35 million for the quarter, compared to analyst estimates of $299.23 million. Progyny had a return on equity of 10.71% and a net margin of 4.46%.Progyny’s revenue for the quarter was up 9.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.11 earnings per share. Progyny has set its FY 2025 guidance at 1.790-1.820 EPS. Q4 2025 guidance at 0.370-0.400 EPS. As a group, equities analysts predict that Progyny, Inc. will post 0.6 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on PGNY. JPMorgan Chase & Co. increased their price objective on shares of Progyny from $23.00 to $25.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 26th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $28.00 price target (up previously from $26.00) on shares of Progyny in a report on Friday, August 8th. Raymond James Financial set a $28.00 price target on shares of Progyny in a research report on Friday, August 8th. Wall Street Zen upgraded shares of Progyny from a “hold” rating to a “buy” rating in a research report on Saturday, July 26th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Progyny in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Progyny presently has an average rating of “Moderate Buy” and a consensus target price of $25.44.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.